Table 2.
Associations between MFP-selected, mutually adjusted IgG glycans and incident type 2 diabetes in the EPIC-Potsdam cohort
| Type 2 diabetes in EPIC-Potsdam per SD, HR (95% CI) | |||
|---|---|---|---|
| Model 1 (n = 2,804) | Model 2 (n = 2,801) | Model 3 (n = 2,678) | |
| IgG-GP | |||
| IgG-GP7 | 0.84 (0.77–0.93) | 0.96 (0.87–1.07) | 0.99 (0.88–1.11) |
| IgG-GP8 | 0.81 (0.73–0.89) | 0.88 (0.78–1.00) | 0.88 (0.77–1.01) |
| IgG-GP9 | 0.83 (0.75–0.91) | 0.86 (0.77–0.96) | 0.89 (0.79–1.00) |
| IgG-GP11 | 1.24 (1.11–1.39) | 1.21 (1.08–1.36) | 1.13 (1.00–1.28) |
| IgG-GP19 | 0.85 (0.77–0.93) | 0.98 (0.88–1.09) | 1.04 (0.92–1.17) |
| IgG glycan score for type 2 diabetes risk | 1.49 (1.35–1.65) | 1.29 (1.15–1.44) | 1.21 (1.08–1.35) |
The shown IgG-GPs were independently associated with type 2 diabetes risk in MFP models (MFP selection based on model 1). The HRs of single IgG-GPs are mutually adjusted. The IgG glycan score for type 2 diabetes risk is a linear combination of the selected glycans, weighted by the regression coefficient from the mutually adjusted Cox model. Model 1 is adjusted for age (strata variable) and sex. Model 2 is additionally adjusted for education (three categories), smoking (four categories), alcohol intake (six categories), physical activity (sports, biking h/week), BMI, waist circumference, prevalent hypertension, antihypertensive and lipid-lowering drugs, and use of aspirin. Model 3 is model 2 adjusted for estimated glomerular filtration rate, total cholesterol, HDL, triglycerides, hs-CRP, and adiponectin. Boldface indicates significance after FDR correction.